Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade

Figures & data

Figure 1. Pre-clinical and clinical evidence for the efficacy of immunogenic chemotherapy plus immune checkpoint blockade in lung cancer. In mouse studies, the induction of immunogenic cell death (ICD) by crizotinib or doxorubicin sensitizes established orthotopic lung cancers to subsequent immunotherapy with immune checkpoint blockade. Consistently, non-small cell lung cancer patients responded to the combination of ICD-inducing chemoradiotherapy or amrubicin with immune checkpoint blockade by an improved overall survival. An ongoing trial evaluates the combination of lurbinectedin with PD-L1 targeting immunotherapy against small cell lung cancers